ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
From Detection to Direction: Signatera MRD testing and its impact in CRC
Watch Video
-
Understanding the IMvigor011 Study: How Signatera™ Helps Guide Bladder Cancer Treatment
Read Article
-
Using ctDNA to Inform Treatment in MIBC
Discover how personalized ctDNA testing is transforming care for patients with muscle-invasive bladder cancer (MIBC). This 30-minute webinar includes results from two landmark Phase 3 studies—IMvigor0
Watch Video
-
ctDNA Monitoring in Ovarian Cancer Patients Receiving PARPi
Toboni, Michael D, et al. Gynecologic Oncology 204 (2026)
Read More
-
Beyond the Image: New Opportunities in Gynecologic Cancer Testing
Natera hosted esteemed speakers Kathleen Moore, MD, Thomas J. Herzog, MD, and Stephanie Lheureux, MD, PhD, for an interesting discussion on the value of MRD in gynecologic oncology
Watch Video
-
Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development
Watch Video
-
Shared Decision Making Worksheet
Read More
-
Transforming Colorectal Cancer Management With Tumor-Informed MRD Testing
Read More
-
Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC
Read More
-
Facing Recurrence Again? How MRD Testing Can Support You Every Step of the Way
Read Article
-
Navigating Lung Cancer with Confidence: Making the Most of the Natera Patient Portal
Read Article
-
How MRD Testing for Recurrence and IO Therapy Provides Peace of Mind
Read Article
-
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma the rando
Long, Georgina V, et al. Nature Medicine 2025
Read More
-
Kyle’s Colon Cancer Story
Read Article
-
Optimizing Breast Cancer Surveillance: A team approach with MRD testing
Watch Video
-
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274
Galsky MD, Gschwend JE, Milowsky MI, et al. Ann Oncol. 2025
Read More
-
Neoadjuvant immunotherapy in mismatch-repair proficient colon cancers
Tan PB, Verschoor YL, van den Berg JG, et al. Nature. 2025
Read More
-
Advancing GYN Oncology Care Using ctDNA Monitoring with Signatera™: Clinical Insights and Real-World Application
Watch Video
-
Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1
Read More
-
Loading More...
